Gila Therapeutics is a clinical-stage biotherapeutic company focused on pharmacological treatment of obesity employing intra-oral application of naturally occurring satiety hormones to induce early fullness, leading to weight loss. Targeting a unique and recently discovered direct neural pathway between the tongue and brain, Gila is developing formulations that when applied to the tongue prior to meals directly stimulates the brain’s satiety centers intended to reduce food intake without any systemic exposure.

Gila, based in Minnesota, was founded in 2014 by Andres Acosta & Sergei Zolotukhin; later that year Thomas Vasicek joined as CEO.

http://www.gilatherapeutics.com/